



US007897349B2

(12) **United States Patent**
Siegler et al.

(10) **Patent No.:** **US 7,897,349 B2**
(45) **Date of Patent:** **Mar. 1, 2011**

(54) **MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AS MARKER FOR UROLOGICAL INFLAMMATORY DISEASE**

(75) Inventors: **Katherine Meyer Siegler**, Seminole, FL (US); **Pedro L. Vera**, Largo, FL (US)

(73) Assignee: **The United States of America as represented by the Department of Veterans Affairs**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 559 days.

(21) Appl. No.: **11/024,405**

(22) Filed: **Dec. 30, 2004**

(65) **Prior Publication Data**

US 2005/0176039 A1 Aug. 11, 2005

Related U.S. Application Data

(60) Provisional application No. 60/532,899, filed on Dec. 30, 2003.

(51) **Int. Cl.**
G01N 33/53 (2006.01)

(52) **U.S. Cl.** **435/7.1**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,503,986 A * 4/1996 Steers et al. 435/7.92
6,008,003 A * 12/1999 Haak-Frendscho et al. . 435/7.23
6,043,044 A 3/2000 Hudson et al.
2005/0054117 A1 3/2005 Giroir et al.

FOREIGN PATENT DOCUMENTS

WO WO 2004/076679 * 9/2004

OTHER PUBLICATIONS

Vera et al. 'Macrophage migration inhibitory factor is released as a complex with alpha1-inhibitor-3 in the intraluminal fluid during bladder inflammation in the rat.' J. Urology. 174:338-343.*
Joshi et al. 'Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF).' Res. Comm. Molec. Path. Pharm. 107(1 & 2):13-20, 2000.*
Meyer Siegler et al. 'Intravesical antibody against macrophage migration inhibitory factor (MIF) reduced substance P induced inflammatory changes in the rat bladder.' Program No. 608.8 2003 Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience, 2003.*
Vera et al. 'Macrophage migration inhibitory factor (MIF) is upregulated in viscerovisceral interactions at the organ and central nervous system levels.' Program No. 608.9. 2003 Abstract Viewer/Itinerary Planner. Washington, DC:Society for Neuroscience, 2003.*
Meyer-Siegler et al. 'Proinflammatory cytokine upregulation in central and peripheral tissue innervation the bladder in an endotoxin

induced model of rat bladder inflammation.' Program No. 71.8. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002.*
Vera et al. 'Macrophage migration inhibitory factor (MIF) and cyclooxygenase-2 (COX-2) are upregulated in an acid-model of bladder inflammation in rats.' Program No. 71.1. 2002 Abstract Viewer/Itinerary PLanner. Washington, DC: Society for Neuroscience, 2002.*
Pollock et al. 'Laboratory techniques for detection of urinary tract infection and assessment of value.' Am. J. Med. 75(1B):79-84, 1983.*
Meyer-Siegler et al. 'Macrophage migration inhibitory factor is increased in the urine of patients with urinary tract infection: macrophage migration inhibitory factor-protein complexes in human urine.' J. Urol. 175:1523-1528, 2006.*
Otukesh et al. 'Urine macrophage migration inhibitory factor (MIF) in children with urinary tract infection: a possible predictor of acute pyelonephritis.' Pediatr. Nephrol. Epub Sep. 18, 2008.*
Otukesh et al. 'Urine macrophage migration inhibitory factor in pediatric systemic lupus erythematosus.' Clin. Rheumatol. 26:2105-2107, 2007.*
Matsumoto et al. 'Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis.' Clin. Exp. Immunol. 139:338-347, 2004.*
Brown et al. 'Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis.' J. Am. Soc. Nephrol. 13:S7-S13, 2002.*
Brown et al. 'Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection.' 17(12):1777-1783, 2001.*
Matsumoto et al. 'Urinary levels of macrophage migration inhibitory factor in patients with IgA nephropathy.' Nephron 92:309-315, 2002.*
Chai et al. 'Diagnosis of the painful bladder syndrome: current approaches to diagnosis.' Clin. Obst. & Gynec. 45(1):250-258, 2002.*
Erickson et al. 'Urine Markers of Interstitial Cystitis.' Urology 57(Suppl 6A): 15-21, 2001.*
Fernandez et al. 'Anatomical location of macrophage migration inhibitory factor in urogenital tissues, peripheral ganglia and lumbosacral spinal cord of the rat.' Program No. 608.7 Abstract Viewer/Itinerary PLanner. Washington, DC: Society for Neuroscience, 2003.*
Vera et al. 'Anatomical location of macrophage migration inhibitory factor in urogenital tissues, peripheral ganglia and lumbosacral spinal cord of the rat.' BMC Neuroscience 4:17, 2003.*

(Continued)

Primary Examiner — Nora M Rooney
(74) *Attorney, Agent, or Firm* — Klarquist Sparkman, LLP

(57) **ABSTRACT**

The present invention relates to the association between detecting and quantifying the presence of macrophage migration inhibitory factor (MIF) in urine, bladder and prostate tissues for the purpose of diagnosis and prognosis of urological inflammatory. In addition, methods to inactivate MIF activity by use of antibodies or specific MIF inhibitors can be used to treat these diseases. For instance, such diseases as chronic pelvic pain syndrome, non-bacterial prostatitis, and interstitial cystitis may be mediated by MIF release. Periodic assays for MIF could be conducted for a patient to determine if the patient's MIF urine levels are high or increasing. In addition, intravesical MIF antibodies or other MIF-specific inhibitors would reduce or ameliorate these pelvic diseases.

8 Claims, No Drawings